Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Relapsed B-Cell Lymphomas or Leukemias
NCT02153580Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Oct 2014
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and B-cell prolymphocytic leukemia (B-PLL) (2 arms), sponsored by City of Hope. Primary endpoints: Toxicity profile of T-cell infusion at 15 years and Dose-limiting toxicity rate at 28 days. Started Oct 2014; status: active, not recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on NCT02153580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153580.